Translate page



David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)






Managing TKI toxicities
Dr Naranie Shanmunagathan, Royal Adelaide Hospital / SA Pathology / SAHMRI

  • Imatinib including bone health
  • Nilotinib including; 5 year follow-up of ENESTnd, hypercholeraemia and hyperglcaemia and prolonged QTc
  • Dasatinib including; 5-year follow-up of DASISION, potential strategy to reduce pleural effusions and management of DAS associated pulmonary toxicity
  • Bosutinib
  • Ponatinib
  • Cardiovascular toxicity and TKI's
  • Pancreatitis
  • Managing haematological toxicity
  • Summary


David Yeung 3  

Allograft - still a role in CML?
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

  • Patient case
  • Allogeneic stem cell transplantation: the most successul immunotherapy in CML
  • German IIIA study
  • Impact of drug development on the use of stem cell transplantation
  • Strategies to reduce the risk of disease relapse in patients allografted in CML
  • EBMT score for allo SCT in CML
  • Graft source: BM better than PDSC in CP-CML
  • Long-term follow-up after transplant for CML
  • Summary

Susan Branford



Monitoring TFR - Challenges
A/Prof. Susan Branford, SA Pathology / Universities of Adelaide and South Australia

  • Gold standards of monitoring in CML
  • Molecular monitoring for best patient outcomes
  • Milestone molecular responses in the first 12 months
  • Long-term molecular monitoring is recommended for prediction of resistance
  • IM resistant BCR-ABL1 kinase domain mutations
  • Long-term molecular monitoring of responsing patients is important to monitor adherence
  • Regular molecular monitoring is recommended for optimal disease management
  • Summary